{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:30:47Z","timestamp":1790890247659,"version":"4.1.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:00:00Z","timestamp":1746403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Asprosin is a newly discovered adipokine, it is associated with the insulin resistance, lipid metabolism disorder, diabetes and obesity. However, there have been no reports on the relationship between asprosin and type 2 diabetic patients with obesity. This study aims to investigate the relationship between serum asprosin and type 2 diabetic patients with obesity in the community.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A total of 491 patients with Type 2 Diabetes Mellitus (T2DM) were recruited from Zhuoma Community Care Station and Chengbei West Street Community Care Service Center in Changzhi City of Shanxi Province from November 2019 to July 2021. Patients were divided into the Normal group (n= 145), Overweight group (n=201) and Obesity group (n= 145). The t-test, Mann\u2013Whitney U test, and \u03c7\u00b2 test were used to compare indicators between the Normal group, Overweight group and Obesity group. Pearson or Spearman correlation analysis was adopted to evaluate the correlation between serum asprosin and other clinical data. Multivariate logistic regression analysis was applied to analyze the influencing factors on obesity. In addition, the diagnostic ability of asprosin to detect type 2 diabetic patients with obesity was tested using receiver operating characteristic (ROC) curve analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with patients with normal weight, the circulating level of asprosin was significantly higher in the obese group than in the normal weight and overweight group (P &amp;lt;0.05). Asprosin was positively correlated with Systolic Blood Pressure(SBP), Body Mass Index (BMI), Waistline, serum uric acid (SUA), aspartate transaminase (AST), creatinine(CRE), and negatively correlated with alanine aminotransferase(ALT). In addition, serum asprosin was significantly correlated with BMI even after adjusting for age, sex, SBP and ALT, SUA, glycosylated hemoglobin (HbA1c), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG) and glomerular filtration rate (eGFR) ((P &amp;lt; 0.05). Compared with the patients in the lowest tertile of serum asprosin (&amp;lt;250.7 pg\/mL), patients with asprosin between 250.7\u2013314.0 pg\/mL [OR (95% CI) is 1.774 (0.978-3.218), P &amp;lt; 0.05] and asprosin &amp;gt;314 pg\/mL [OR (95% CI) is 8.406 (4.788-14.758), P &amp;lt; 0.05] have a higher risk of obesity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Serum asprosin was correlated with obesity in community-based type 2 diabetic patients with obesity. Additionally, the risk of obesity was obviously increased with the raise of asprosin. Therefore, we speculate that serum asprosin could be used as a risk predictor of type 2 diabetic patients with obesity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2025.1535668","type":"journal-article","created":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:10:35Z","timestamp":1746403835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["The correlation between serum asprosin and type 2 diabetic patients with obesity in the community"],"prefix":"10.3389","volume":"16","author":[{"given":"Dong","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyu","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minggang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linxin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,5,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/advances\/nmy055","article-title":"Humans against obesity: who will win","volume":"10","author":"Caballero","year":"2017","journal-title":"Adv Nutr"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00379.2020","article-title":"Adipose tissue inflammation and metabolic dysfunction in obesity","volume":"320","author":"Kawai","year":"2021","journal-title":"Am J Physiol Cell Physiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-88","article-title":"The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis","volume":"9","author":"Guh","year":"2009","journal-title":"BMC Public Health"},{"key":"B4","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1186\/s12967-019-2096-8","article-title":"Metabolic signature of obesity-associated insulin resistance and type 2 diabetes","volume":"17","author":"Al-Sulaiti","year":"2021","journal-title":"J Transl Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4350","article-title":"Insulin action and resistance in obesity and type 2 diabetes","volume":"23","author":"Czech","year":"2017","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2521096","article-title":"Saliva and blood asprosin hormone concentration associated with obesity","volume":"2019","author":"Ugur","year":"2017","journal-title":"Int J Endocrinol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1159\/000503808","article-title":"Serum asprosin concentrations are increased and associated with insulin resistance in children with obesity","volume":"75","author":"Wang","year":"2019","journal-title":"Ann Nutr Metab"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/ped.14176","article-title":"Increased serum circulating asprosin levels in children with obesity","volume":"62","author":"S\u00fcnnet\u00e7i Silistre","year":"2020","journal-title":"Pediatr In"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-018-0248-1","article-title":"Serum asprosin levels and bariatric surgery outcomes in obese adults","volume":"43","author":"Wang","year":"2019","journal-title":"Int J Obes (Lond)"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2017.10.034","article-title":"Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride","volume":"489","author":"Zhang","year":"2019","journal-title":"Clin Chim Acta"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/jdi.13148","article-title":"Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus","volume":"11","author":"Zhang","year":"2020","journal-title":"J Diabetes Investig"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2021.211015","article-title":"Two important players for type 2 diabetes mellitus: metrnl and asprosin","volume":"68","author":"Timurkaan","year":"2022","journal-title":"Clin Lab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7375294","article-title":"Plasma asprosin levels are associated with glucose metabolism, lipid, and sex hormone profiles in females with metabolic-related diseases","volume":"2018","author":"Li","year":"2018","journal-title":"Mediators Inflammation"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1101091","article-title":"Asprosin in health and disease, a new glucose sensor with central and peripheral metabolic effects","volume":"13","author":"Farrag","year":"2023","journal-title":"Front Endocrinol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S","article-title":"Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation","volume":"15","author":"Alberti","year":"1998","journal-title":"Diabetes Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.045170","article-title":"Canadian guidelines for body weight classification in adults: application in clinical practice to screen for overweight and obesity and to assess disease risk","volume":"172","author":"Douketis","year":"2005","journal-title":"CMAJ"},{"key":"B17","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nri2921","article-title":"Adipokines in inflammation and metabolic disease","volume":"11","author":"Ouchi","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.mce.2019.03.001","article-title":"Asprosin impairs insulin secretion in response to glucose and viability through TLR4\/JNK-mediated inflammation","volume":"486","author":"Lee","year":"2019","journal-title":"Mol Cell Endocrinol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.29835","article-title":"Asprosin promotes \u03b2-cell apoptosis by inhibiting the autophagy of \u03b2-cell via AMPK-mTOR pathway","volume":"236","author":"Wang","year":"2021","journal-title":"J Cell Physiol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13098-020-00564-w","article-title":"Serum concentration of asprosin in new-onset type 2 diabetes","volume":"12","author":"Naiemian","year":"2022","journal-title":"Diabetol Metab Syndr"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9471583","article-title":"Plasma asprosin concentrations are increased in individuals with glucose dysregulation and correlated with insulin resistance and first-phase insulin secretion","volume":"2018","author":"Wang","year":"2018","journal-title":"Mediators Inflammation"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23471","article-title":"Investigation of serum and adipose tissue levels of asprosin in patients with severe obesity undergoing sleeve gastrectomy","volume":"30","author":"Cantay","year":"2022","journal-title":"Obes (Silver Spring)"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2021.155477","article-title":"Asprosin serum levels and glucose homeostasis in children with obesity","volume":"142","author":"Corica","year":"2022","journal-title":"Cytokine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1159\/000500523","article-title":"Decreased circulating levels of asprosin in obese children","volume":"91","author":"Long","year":"2019","journal-title":"Horm Res Paediatr"},{"key":"B25","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s12967-022-03542-0","article-title":"Asprosin inhibits macrophage lipid accumulation and reduces atherosclerotic burden by up-regulating ABCA1 and ABCG1 expression via the p38\/Elk-1 pathway","volume":"20","author":"Zou","year":"2022","journal-title":"J Transl Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.805700","article-title":"Meal-related asprosin serum levels are affected by insulin resistance and impaired fasting glucose in children with obesity","volume":"12","author":"Corica","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155184","article-title":"Combination of asprosin and adiponectin as a novel marker for diagnosing non-alcoholic fatty liver disease","volume":"134","author":"Ke","year":"2020","journal-title":"Cytokine"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6622129","article-title":"High serum asprosin levels are associated with presence of metabolic syndrome","volume":"2021","author":"Hong","year":"2021","journal-title":"Int J Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S361808","article-title":"Association between serum asprosin and diabetic nephropathy in patients with type 2 diabetes mellitus in the community: A cross-sectional study","volume":"15","author":"Xu","year":"2021","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-021-00444-x","article-title":"Increased asprosin is associated with nonalcoholic fatty liver disease in children with obesity","volume":"17","author":"Liu","year":"2021","journal-title":"World J Pediatr"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.31838\/srp.2020.12.262","article-title":"Correlation between serum asprosin level and oxidative stress in Iraqi patients with type ii diabetes mellitus","volume":"11","author":"Ahmed Alobaidi","year":"2020","journal-title":"Syst Rev Pharm"},{"key":"B32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5603\/EP.a2020.0059","article-title":"Investigation of plasma asprosin and saliva levels in newly diagnosed type 2 diabetes mellitus patients treated with metformin","volume":"72","author":"Gozel","year":"2021","journal-title":"Endokrynol Pol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13098-021-00668-x","article-title":"Increased serum asprosin is correlated with diabetic nephropathy","volume":"13","author":"Wang","year":"2021","journal-title":"Diabetol Metab Syndr"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e31334","DOI":"10.1097\/MD.0000000000031334","article-title":"Effects of GLP-1 receptor agonists on asprosin levels in normal weight or overweight\/obesity patients with type 2 diabetes mellitus","volume":"101","author":"Dai","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13098-021-00652-5","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on the levels of serum asprosin in patients with newly diagnosed type 2 diabetes mellitus","volume":"13","author":"Jiang","year":"2021","journal-title":"Diabetol Metab Syndr"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.63784^","article-title":"Asprosin-neutralizing antibodies as a treatment for metabolic syndrome","volume":"10","author":"Mishra","year":"2021","journal-title":"Elife"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1535668\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T00:10:36Z","timestamp":1746403836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2025.1535668\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,5]]},"references-count":36,"alternative-id":["10.3389\/fendo.2025.1535668"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2025.1535668","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,5]]},"article-number":"1535668"}}